A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine

Sagar Munjal, Elimor Brand-Schieber, Kent Allenby, Egilius L H Spierings, Roger K Cady, Alan M Rapoport, Sagar Munjal, Elimor Brand-Schieber, Kent Allenby, Egilius L H Spierings, Roger K Cady, Alan M Rapoport

Abstract

Background: DFN-02 is a novel intranasal spray formulation composed of sumatriptan 10 mg and a permeation-enhancing excipient comprised of 0.2% 1-O-n-Dodecyl-β-D-Maltopyranoside (DDM). This composition of DFN-02 allows sumatriptan to be rapidly absorbed into the systemic circulation and exhibit pharmacokinetics comparable to subcutaneously administered sumatriptan. Rapid rate of absorption is suggested to be important for optimal efficacy. The objective of this study was to evaluate the safety and tolerability of DFN-02 (10 mg) in the acute treatment of episodic migraine with and without aura over a 6-month period based on the incidence of treatment-emergent adverse events and the evaluation of results of clinical laboratory tests, vital signs, physical examination, and electrocardiograms.

Methods: This was a multi-center, open-label, repeat-dose safety study in adults with episodic migraine with and without aura. Subjects diagnosed with migraine with or without aura according to the criteria set forth in the International Classification of Headache Disorders, 2nd edition, who experienced 2 to 6 attacks per month with fewer than 15 headache days per month and at least 48 headache-free hours between attacks, used DFN-02 to treat their migraine attacks acutely over the course of 6 months.

Results: A total of 173 subjects was enrolled, 167 (96.5%) subjects used at least 1 dose of study medication and were evaluable for safety, and 134 (77.5%) subjects completed the 6-month study. A total of 2211 migraine attacks was reported, and 3292 doses of DFN-02 were administered; mean per subject monthly use of DFN-02 was 3.6 doses. Adverse events were those expected for triptans, as well as for nasally administered compounds. No new safety signals emerged. Dysgeusia and application site pain were the most commonly reported treatment-emergent adverse events over 6 months (21% and 30.5%, respectively). Most of the treatment-emergent adverse events were mild. There were 5 serious adverse events, all considered unrelated to the study medication; the early discontinuation rate was 22.5% over the 6-month treatment period.

Conclusion: DFN-02 was shown to be well tolerated when used over 6 months to treat episodic migraine acutely.

Keywords: Acute treatment; DDM; Episodic migraine; Intranasal sumatriptan; Long-term safety; Sumatriptan.

Figures

Fig. 1
Fig. 1
Disposition of subjects

References

    1. International Headache Society The International Classification of Headache Disorders, 3rd edition (beta version) Cephalalgia. 2013;33:629–808. doi: 10.1177/0333102413485658.
    1. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–762. doi: 10.1212/WNL.55.6.754.
    1. Mathew NT, Loder EW. Evaluating the triptans. Am J Med. 2005;118(Suppl 1):28s–35s.
    1. Lionetto L, Negro A, Casolla B, et al. Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice. Expert Opin Pharmacother. 2012;13:2369–2380. doi: 10.1517/14656566.2012.730041.
    1. Napoletano F, Lionetto L, Martelletti P. Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity. Expert Opin Pharmacother. 2014;15:303–305. doi: 10.1517/14656566.2014.858120.
    1. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012:Cd008615
    1. IMITREX (sumatriptan succinate) tablets [Prescribing information]. Available at: . Accessed 29 Dec 2016.
    1. Aurora S, Kori S, Barrodale P, et al. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007;47:1443–1446. doi: 10.1111/j.1526-4610.2007.00853.x.
    1. Aurora SK, Kori SH, Barrodale P, et al. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46:57–63. doi: 10.1111/j.1526-4610.2006.00311.x.
    1. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol. 1990;30:405–409. doi: 10.1111/j.1365-2125.1990.tb03791.x.
    1. Mathew NT, Dexter J, Couch J, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49:1271–1276. doi: 10.1001/archneur.1992.00530360073020.
    1. IMITREX (sumatriptan succinate) injection [Prescribing Information]. Available at: . Accessed 29 Dec 2016.
    1. Silberstein SD, Marcus DA. Sumatriptan : treatment across the full spectrum of migraine. Expert Opin Pharmacother. 2013;14:1659–1667. doi: 10.1517/14656566.2013.810209.
    1. Rapoport A. New frontiers in headache therapy. Neurol Sci. 2011;32(Suppl 1):S105–109. doi: 10.1007/s10072-011-0542-3.
    1. FDA Drug Safety Communication: FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patch. Available at: . Accessed 29 Dec 2016.
    1. Goldstein J, Smith TR, Pugach N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012;52:1402–1410. doi: 10.1111/j.1526-4610.2012.02198.x.
    1. Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012:Cd009663
    1. IMITREX (sumatriptan succinate) nasal spray [Prescribing Information]. Available at: . Accessed 29 Dec 2016.
    1. ZOMIG (zomlitriptan) nasal spray [Prescribing Information]. Available at: . Accessed 29 Dec 2016.
    1. Luthringer R, Djupesland PG, Sheldrake CD, et al. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol. 2009;61:1219–1228. doi: 10.1211/jpp.61.09.0012.
    1. ONZETRA Xsail (sumatriptan nasal powder) [Prescribing Information]. Available at: . Accessed 29 Dec 2016.
    1. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002;42(Suppl 1):3–9. doi: 10.1046/j.1526-4610.2002.0420s1003.x.
    1. Macgregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache. 2003;43:19–26. doi: 10.1046/j.1526-4610.2003.03004.x.
    1. Malik SN, Hopkins M, Young WB, et al. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46:773–780. doi: 10.1111/j.1526-4610.2006.00437.x.
    1. Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol. 2015;11:175–177. doi: 10.1517/17425255.2015.982089.
    1. Pillion DJ, Hosmer S, Meezan E. Dodecylmaltoside-mediated nasal and ocular absorption of lyspro-insulin: independence of surfactant action from multimer dissociation. Pharm Res. 1998;15:1637–1639. doi: 10.1023/A:1011975721569.
    1. Ahsan F, Arnold J, Meezan E, et al. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm Res. 2001;18:1742–1746. doi: 10.1023/A:1013330815253.
    1. Pillion DJ, Ahsan F, Arnold JJ, et al. Synthetic long-chain alkyl maltosides and alkyl sucrose esters as enhancers of nasal insulin absorption. J Pharm Sci. 2002;91:1456–1462. doi: 10.1002/jps.10150.
    1. Mustafa F, Yang T, Khan MA, et al. Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin. J Pharm Sci. 2004;93:675–683. doi: 10.1002/jps.10579.
    1. Maggio ET. Intravail: highly effective intranasal delivery of peptide and protein drugs. Expert Opin Drug Deliv. 2006;3:529–539. doi: 10.1517/17425247.3.4.529.
    1. Eley JG, Triumalashetty P. In vitro assessment of alkylglycosides as permeability enhancers. AAPS PharmSciTech. 2001;2:E19. doi: 10.1208/pt020319.
    1. Tirumalasetty PP, Eley JG. Evaluation of dodecylmaltoside as a permeability enhancer for insulin using human carcinoma cells. J Pharm Sci. 2005;94:246–255. doi: 10.1002/jps.20234.
    1. Munjal S, Gautam A, Offman E, et al. A randomized trial comparing the pharmacokinetics, safety, and tolerability of DFN-02, an intranasal sumatriptan spray containing a permeation enhancer, with intranasal and subcutaneous sumatriptan in healthy adults. Headache. 2016;56:1455–1465. doi: 10.1111/head.12905.
    1. International Headache Society The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160.
    1. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology. 1997;49:1225–1230. doi: 10.1212/WNL.49.5.1225.
    1. Wendt J, Cady R, Singer R, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther. 2006;28:517–526. doi: 10.1016/j.clinthera.2006.03.013.
    1. Walling AD, Woolley DC, Molgaard C, et al. Patient satisfaction with migraine management by family physicians. J Am Board Fam Pract. 2005;18:563–566. doi: 10.3122/jabfm.18.6.563.
    1. Gawel M, Aschoff J, May A, et al. Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study. J Headache Pain. 2005;6:405–411. doi: 10.1007/s10194-005-0237-3.
    1. Weidmann E, Unger J, Blair S, et al. An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations. Clin Ther. 2003;25:235–246. doi: 10.1016/S0149-2918(03)90031-2.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir